In the case of Crohn’s disease, when the diagnosis is made in a high-risk situation—that is, in the presence of severe growth retardation, perianal disease, stricture, or widespread and deep ulcers—it is recommended that treatment with anti-TNF drugs be initiated without delay, prior to the administration of first-line treatments [16]. This evidence concerns the gene TNF and Crohn disease.